Myriad Genetics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Myriad Genetics Inc MYGN.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of fifteen analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from zero cents to 5 cents per share.

• Revenue rose 11.2% to $213.30 million from a year ago; analysts expected $210.73 million.

• Myriad Genetics Inc's reported EPS for the quarter was a loss of 24 cents​.

• The company reported a quarterly loss of $22.1 million.

• Myriad Genetics Inc shares had fallen by 35.9% this quarter and lost 8.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 23.4% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy," 4 "hold" and 4 "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Myriad Genetics Inc is 30.00

This summary was machine generated from LSEG data November 8 at 04:41 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)